Sobr Safe Files to Sell 3.97M Shares of Common Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 13 2026
0mins
Should l Buy SOBR?
Sobr Safe files to sell 3.97M shares of common stock for holders
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SOBR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SOBR
About SOBR
SOBR Safe, Inc. is a provider of transdermal alcohol detection solutions. It provides non-invasive technology to quickly and discretely monitor, detect and identify the presence of alcohol in individuals. Its non-invasive technologies are integrated within its scalable and patent-pending software platform, SOBRsafe, producing statistical, measurable business and user data. Its SOBRcheck device is a patent-pending, touch-based identity verification and alcohol detection solution. Its SOBRsure device is a patent-pending, fitness-style wearable band with an alcohol monitoring and detection solution intended for discrete, low-profile and voluntary use, providing qualified, real-time alcohol monitoring and GPS tracking. The SOBRsafe technology can also be deployed across numerous additional devices for various uses. Its segment is designed to enable customers to purchase products directly through channel partners, sales agents or through its digital enterprise and consumer channels.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SOBR Safe Closes $2 Million Private Placement Issuing 1,290,324 Shares
- Successful Financing: SOBR Safe has closed a $2 million private placement, issuing 1,290,324 shares of common stock and associated warrants at a price of $1.55 per share, which will provide essential funding for the company's operations.
- Warrant Details: The issued warrants include Series C and Series D, allowing the purchase of 1,290,324 shares at an exercise price of $1.30 per share, with Series C valid for five years and Series D for two years, enhancing potential returns for investors.
- Planned Use of Funds: The company intends to use the net proceeds from this offering for working capital and general corporate purposes, aiming to improve financial flexibility and competitive positioning in the market.
- Compliance Statement: The securities were offered in compliance with Section 4(a)(2) of the Securities Act of 1933, ensuring they are provided only to accredited investors, demonstrating the company's commitment to regulatory compliance and reducing legal risks.
See More
SOBR Safe Shares Drop Over 11%, Impacting Market Confidence
- Stock Volatility: SOBR Safe shares fell over 11% in recent Friday premarket trading, indicating market concerns about the company's future performance, which could negatively impact investor confidence and capital inflows.
- Market Reaction: This decline may be linked to the company's recent financial performance or changes in market conditions, reflecting investor skepticism about its business model and potentially affecting its market valuation.
- Investor Sentiment: The significant stock drop may prompt investors to reassess their positions in SOBR Safe, leading to short-term capital outflows that could hinder the company's financing capabilities.
- Need for Strategic Adjustment: In light of the stock decline, SOBR Safe may need to reevaluate its market strategy and operational efficiency to restore investor confidence and enhance future shareholder value.
See More
Dynavax Technologies Surges 38.19% Following Sanofi Acquisition Announcement
- Acquisition Surge: Dynavax Technologies' stock price soared 38.19% following Sanofi's acquisition announcement, indicating strong market reaction and expected enhancement of Dynavax's market position in the vaccine sector.
- Transaction Context: This acquisition will allow Sanofi to expand its vaccine product line, further solidifying its leadership in the biopharmaceutical industry while providing Dynavax with stronger resource support to accelerate its R&D efforts.
- Market Trend Analysis: Dynavax's stock shows a strong price trend over short, medium, and long terms, reflecting investor confidence in its future growth potential, especially against the backdrop of sustained vaccine demand.
- Investor Confidence Boost: This acquisition not only elevates Dynavax's market valuation but may also attract more investor attention, further driving its stock price up and enhancing its competitive edge in the market.
See More
Davis Commodities Reports $95M Revenue in H1, Up 42.1%
- Significant Revenue Growth: Davis Commodities Ltd reported a revenue of $95 million for the first half ending June 30, marking a 42.1% increase from $66.9 million a year earlier, indicating strong performance in the agricultural commodity trading sector and boosting market confidence.
- Stock Price Surge: Following the earnings report, Davis Commodities' shares jumped 5.6% to $0.25 in pre-market trading, reflecting investor optimism regarding the company's future growth potential.
- Positive Market Reaction: The stock price increase post-earnings release indicates market recognition of Davis Commodities' performance, which may attract more investor interest and further drive the stock price upward.
- Optimistic Industry Outlook: With the ongoing demand for agricultural commodities, the strong earnings report not only enhances Davis Commodities' market position but also potentially provides funding for future expansion and investments.
See More
Dynavax Technologies Corp. Shares Surge 38.2% Following Sanofi Acquisition Announcement
- Acquisition Announcement Surge: Sanofi's announcement to acquire Dynavax Technologies led to a 38.2% surge in its stock price on Wednesday, closing at $15.38, indicating strong market optimism about the deal and potentially enhancing Dynavax's market position.
- Increased Investor Attention: This acquisition not only attracted widespread investor interest but may also provide Dynavax with additional resources and support, accelerating its vaccine development process and strengthening its competitive edge in the biopharmaceutical sector.
- Positive Market Reaction: The significant rise in Dynavax's stock price reflects a positive market response to merger activities in the biopharmaceutical industry, potentially prompting other companies to consider similar strategic moves to enhance market share.
- Future Growth Potential: Sanofi's acquisition intent signifies recognition of Dynavax's technology and product portfolio, which is expected to provide robust support for future revenue growth and market expansion.
See More
SOBR Safe Inc. Completes Private Placement, Stock Volatility Noted
- Private Placement: SOBR Safe announced definitive agreements to issue 1.29 million shares at $1.55 each, aiming to raise approximately $2 million in gross proceeds, with net proceeds allocated for working capital and general corporate purposes, indicating a pressing need for liquidity.
- Stock Volatility: Despite a significant 82.31% increase to $2.37 during regular trading, the stock fell 14.35% to $2.03 in after-hours trading, reflecting market concerns about the company's future prospects, especially given an 80.41% decline over the past year.
- Market Performance: With a market capitalization of $3.59 million, SOBR Safe's current trading price is close to its 52-week low of $1.27, indicating a prolonged downtrend, suggesting that while short-term opportunities may exist, the overall outlook remains challenging.
- Technical Indicators: The company's relative strength index (RSI) stands at 62.53, indicating some market activity; however, the negative price trend is confirmed across all time frames, signaling investors should approach with caution.
See More
SOBR Safe Closes $2 Million Private Placement Issuing 1,290,324 Shares
- Successful Financing: SOBR Safe has closed a $2 million private placement, issuing 1,290,324 shares of common stock and associated warrants at a price of $1.55 per share, which will provide essential funding for the company's operations.
- Warrant Details: The issued warrants include Series C and Series D, allowing the purchase of 1,290,324 shares at an exercise price of $1.30 per share, with Series C valid for five years and Series D for two years, enhancing potential returns for investors.
- Planned Use of Funds: The company intends to use the net proceeds from this offering for working capital and general corporate purposes, aiming to improve financial flexibility and competitive positioning in the market.
- Compliance Statement: The securities were offered in compliance with Section 4(a)(2) of the Securities Act of 1933, ensuring they are provided only to accredited investors, demonstrating the company's commitment to regulatory compliance and reducing legal risks.
See More
SOBR Safe Shares Drop Over 11%, Impacting Market Confidence
- Stock Volatility: SOBR Safe shares fell over 11% in recent Friday premarket trading, indicating market concerns about the company's future performance, which could negatively impact investor confidence and capital inflows.
- Market Reaction: This decline may be linked to the company's recent financial performance or changes in market conditions, reflecting investor skepticism about its business model and potentially affecting its market valuation.
- Investor Sentiment: The significant stock drop may prompt investors to reassess their positions in SOBR Safe, leading to short-term capital outflows that could hinder the company's financing capabilities.
- Need for Strategic Adjustment: In light of the stock decline, SOBR Safe may need to reevaluate its market strategy and operational efficiency to restore investor confidence and enhance future shareholder value.
See More
Dynavax Technologies Surges 38.19% Following Sanofi Acquisition Announcement
- Acquisition Surge: Dynavax Technologies' stock price soared 38.19% following Sanofi's acquisition announcement, indicating strong market reaction and expected enhancement of Dynavax's market position in the vaccine sector.
- Transaction Context: This acquisition will allow Sanofi to expand its vaccine product line, further solidifying its leadership in the biopharmaceutical industry while providing Dynavax with stronger resource support to accelerate its R&D efforts.
- Market Trend Analysis: Dynavax's stock shows a strong price trend over short, medium, and long terms, reflecting investor confidence in its future growth potential, especially against the backdrop of sustained vaccine demand.
- Investor Confidence Boost: This acquisition not only elevates Dynavax's market valuation but may also attract more investor attention, further driving its stock price up and enhancing its competitive edge in the market.
See More
Davis Commodities Reports $95M Revenue in H1, Up 42.1%
- Significant Revenue Growth: Davis Commodities Ltd reported a revenue of $95 million for the first half ending June 30, marking a 42.1% increase from $66.9 million a year earlier, indicating strong performance in the agricultural commodity trading sector and boosting market confidence.
- Stock Price Surge: Following the earnings report, Davis Commodities' shares jumped 5.6% to $0.25 in pre-market trading, reflecting investor optimism regarding the company's future growth potential.
- Positive Market Reaction: The stock price increase post-earnings release indicates market recognition of Davis Commodities' performance, which may attract more investor interest and further drive the stock price upward.
- Optimistic Industry Outlook: With the ongoing demand for agricultural commodities, the strong earnings report not only enhances Davis Commodities' market position but also potentially provides funding for future expansion and investments.
See More
Dynavax Technologies Corp. Shares Surge 38.2% Following Sanofi Acquisition Announcement
- Acquisition Announcement Surge: Sanofi's announcement to acquire Dynavax Technologies led to a 38.2% surge in its stock price on Wednesday, closing at $15.38, indicating strong market optimism about the deal and potentially enhancing Dynavax's market position.
- Increased Investor Attention: This acquisition not only attracted widespread investor interest but may also provide Dynavax with additional resources and support, accelerating its vaccine development process and strengthening its competitive edge in the biopharmaceutical sector.
- Positive Market Reaction: The significant rise in Dynavax's stock price reflects a positive market response to merger activities in the biopharmaceutical industry, potentially prompting other companies to consider similar strategic moves to enhance market share.
- Future Growth Potential: Sanofi's acquisition intent signifies recognition of Dynavax's technology and product portfolio, which is expected to provide robust support for future revenue growth and market expansion.
See More
SOBR Safe Inc. Completes Private Placement, Stock Volatility Noted
- Private Placement: SOBR Safe announced definitive agreements to issue 1.29 million shares at $1.55 each, aiming to raise approximately $2 million in gross proceeds, with net proceeds allocated for working capital and general corporate purposes, indicating a pressing need for liquidity.
- Stock Volatility: Despite a significant 82.31% increase to $2.37 during regular trading, the stock fell 14.35% to $2.03 in after-hours trading, reflecting market concerns about the company's future prospects, especially given an 80.41% decline over the past year.
- Market Performance: With a market capitalization of $3.59 million, SOBR Safe's current trading price is close to its 52-week low of $1.27, indicating a prolonged downtrend, suggesting that while short-term opportunities may exist, the overall outlook remains challenging.
- Technical Indicators: The company's relative strength index (RSI) stands at 62.53, indicating some market activity; however, the negative price trend is confirmed across all time frames, signaling investors should approach with caution.
See More
